Back to Search
THOMAS WITZIG, M.D.
M.D.
Hematology (Internal Medicine) Physician
NPI: 1508846791IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
27220(MN)
Education
ILLINOIS MEDICAL COLLEGE
Class of 1979
Research & Publications (20)
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
PMID 18569634·Leuk Lymphoma·2008
3-trial
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
PMID 17550749·Mayo Clin Proc·2007
8-other
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
PMID 17380530·Cancer·2007
3-trial
Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
PMID 16997175·Best Pract Res Clin Haematol·2006
6-review
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
PMID 16916489·Curr Treat Options Oncol·2006
6-review
Current treatment approaches for mantle-cell lymphoma.
PMID 16155027·J Clin Oncol·2005
4-observational
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
PMID 15983389·J Clin Oncol·2005
8-other
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
PMID 15657404·J Clin Oncol·2005
3-trial
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
PMID 15452187·J Clin Oncol·2005
3-trial
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
PMID 15045033·Drugs Today (Barc)·2004
6-review
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
PMID 14710398·Semin Oncol·2003
6-review
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
PMID 12663713·J Clin Oncol·2003
8-other
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
PMID 12149300·J Clin Oncol·2002
3-trial
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
PMID 12011122·J Clin Oncol·2002
3-trial
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.
PMID 12006523·Clin Cancer Res·2002
8-other
Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
PMID 11587375·Cancer Chemother Pharmacol·2001
6-review
The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
PMID 11226003·Semin Oncol·2000
8-other
A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders.
PMID 10830741·Leuk Lymphoma·2000
4-observational
Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.
PMID 10690554·Clin Cancer Res·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1508846791
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 47
- Publications
- 20
Are you this provider?
Claim Your Profile